BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 29185589)

  • 21. Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment.
    Mochizuki S; Nishimura N; Inoue A; Murakami K; Nukiwa T; Chohnabayashi N
    Respir Investig; 2012 Sep; 50(3):117-21. PubMed ID: 23021771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical research on stereotactic radiosurgery combined with epithermal growth factor tyrosine kinase inhibitors in the treatment of brain metastasis of non-small cell lung cancer.
    Jia F; Cheng X; Zeng H; Miao J; Hou M
    J BUON; 2019; 24(2):578-584. PubMed ID: 31128009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole-brain radiotherapy plus sequential or simultaneous integrated boost for the treatment of a limited number of brain metastases in non-small cell lung cancer: A single-institution study.
    Qing D; Zhao B; Zhou YC; Zhu HL; Ma DY
    Cancer Med; 2020 Jan; 9(1):238-246. PubMed ID: 31749325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic radiosurgery with whole brain radiotherapy combined with bevacizumab in the treatment of brain metastases from NSCLC.
    Li L; Feng M; Xu P; Wu YL; Yin J; Huang Y; Tan MY; Jinyi L
    Int J Neurosci; 2023 Mar; 133(3):334-341. PubMed ID: 33843421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome and prognostic factors in single brain metastases from small-cell lung cancer.
    Bernhardt D; Adeberg S; Bozorgmehr F; Opfermann N; Hörner-Rieber J; König L; Kappes J; Thomas M; Unterberg A; Herth F; Heußel CP; Warth A; Debus J; Steins M; Rieken S
    Strahlenther Onkol; 2018 Feb; 194(2):98-106. PubMed ID: 29085978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis.
    Olmez I; Donahue BR; Butler JS; Huang Y; Rubin P; Xu Y
    Lung Cancer; 2010 Nov; 70(2):174-9. PubMed ID: 20207442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
    Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
    Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors affecting survival after whole brain radiotherapy in patients with brain metastasized lung cancer.
    Tsakonas G; Hellman F; Gubanski M; Friesland S; Tendler S; Lewensohn R; Ekman S; de Petris L
    Acta Oncol; 2018 Feb; 57(2):231-238. PubMed ID: 28984492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.
    Magnuson WJ; Yeung JT; Guillod PD; Gettinger SN; Yu JB; Chiang VL
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):673-9. PubMed ID: 27034176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.
    Shimato S; Mitsudomi T; Kosaka T; Yatabe Y; Wakabayashi T; Mizuno M; Nakahara N; Hatano H; Natsume A; Ishii D; Yoshida J
    Neuro Oncol; 2006 Apr; 8(2):137-44. PubMed ID: 16510849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.
    Caballero JA; Sneed PK; Lamborn KR; Ma L; Denduluri S; Nakamura JL; Barani IJ; McDermott MW
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):303-9. PubMed ID: 22079723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.
    Besse B; Le Moulec S; Mazières J; Senellart H; Barlesi F; Chouaid C; Dansin E; Bérard H; Falchero L; Gervais R; Robinet G; Ruppert AM; Schott R; Léna H; Clément-Duchêne C; Quantin X; Souquet PJ; Trédaniel J; Moro-Sibilot D; Pérol M; Madroszyk AC; Soria JC
    Clin Cancer Res; 2015 Apr; 21(8):1896-903. PubMed ID: 25614446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of brain metastases from non-small cell lung cancer.
    Baykara M; Kurt G; Buyukberber S; Demirci U; Ceviker N; Algin E; Coskun U; Aykol S; Emmez H; Ozet A; Benekli M
    J Cancer Res Ther; 2014; 10(4):915-21. PubMed ID: 25579528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study.
    Chua D; Krzakowski M; Chouaid C; Pallotta MG; Martinez JI; Gottfried M; Curran W; Throuvalas N
    Clin Lung Cancer; 2010 May; 11(3):176-81. PubMed ID: 20439193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gamma knife treatment for multiple metastatic brain tumors compared with whole-brain radiation therapy.
    Serizawa T; Iuchi T; Ono J; Saeki N; Osato K; Odaki M; Ushikubo O; Hirai S; Sato M; Matsuda S
    J Neurosurg; 2000 Dec; 93 Suppl 3():32-6. PubMed ID: 11143259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case report.
    Stemmler HJ; Weigert O; Krych M; Schoenberg SO; Ostermann H; Hiddemann W
    Anticancer Drugs; 2005 Aug; 16(7):747-9. PubMed ID: 16027524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
    Deng X; Zheng Z; Lin B; Su H; Chen H; Fei S; Fei Z; Zhao L; Jin X; Xie CY
    BMC Cancer; 2017 Jan; 17(1):42. PubMed ID: 28068937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
    Welsh JW; Komaki R; Amini A; Munsell MF; Unger W; Allen PK; Chang JY; Wefel JS; McGovern SL; Garland LL; Chen SS; Holt J; Liao Z; Brown P; Sulman E; Heymach JV; Kim ES; Stea B
    J Clin Oncol; 2013 Mar; 31(7):895-902. PubMed ID: 23341526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival after whole brain radiotherapy for brain metastases from lung cancer and breast cancer is poor in 6325 Dutch patients treated between 2000 and 2014.
    Jeene PM; de Vries KC; van Nes JGH; Kwakman JJM; Wester G; Rozema T; Braam PM; Zindler JD; Koper P; Nuyttens JJ; Vos-Westerman HA; Schmeets I; Niël CGHJ; Hutschemaekers S; van der Linden YM; Verhoeff JJC; Stalpers LJA
    Acta Oncol; 2018 May; 57(5):637-643. PubMed ID: 29276848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.